Ethylamine

Ethylamine

SCHEMBL5574544

CC(C)(C)OC(N)=O.CCN

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.42
LMNA P02545 3/20 0.40
HSD17B10 Q99714 1/20 0.40
DGAT1 O75907 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
CA1 P00915 2/20 0.33
CA7 P43166 2/20 0.33
CA12 O43570 1/20 0.33
CA14 Q9ULX7 1/20 0.33
CTSK P43235 2/20 0.33
TDP1 Q9NUW8 2/20 0.32
CA2 P00918 1/20 0.31
NOS1 P29475 2/20 0.31
GAA P10253 2/20 0.31
KDM4E B2RXH2 1/20 0.31
NOS3 P29474 1/20 0.31
NOS2 P35228 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propane SCHEMBL27464056 0.92 ALOX15 (0.43) ALOX15LMNAHSD17B10DGAT1MAOA
Propylamine SCHEMBL27713757 0.90 LMNA (0.42) ALOX15LMNAHSD17B10DGAT1MAOA
Butane SCHEMBL27617980 0.90 LMNA (0.45) ALOX15LMNAHSD17B10DGAT1MAOA
Alcohol SCHEMBL6545350 0.90 ALOX15 (0.42) ALOX15LMNAHSD17B10DGAT1MAOA
Ethylenediamine SCHEMBL5093336 0.90 ALOX15 (0.36) ALOX15LMNAHSD17B10DGAT1MAOA
SCHEMBL28902273 0.89 DGAT1 (0.42) ALOX15LMNAHSD17B10DGAT1MAOA
SCHEMBL28325001 0.89 DGAT1 (0.42) ALOX15LMNAHSD17B10DGAT1MAOA
SCHEMBL3094 0.89
SCHEMBL30234788 0.89 DGAT1 (0.42) ALOX15LMNAHSD17B10DGAT1MAOA
Ethyl Chloride SCHEMBL28678554 0.87 ALOX15 (0.40) ALOX15LMNAHSD17B10DGAT1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106608863-A Preparation method of landiolol hydrochloride 北京创立科创医药技术开发有限公司 2017-05-03 CN disclosed
CN-103002921-A Functionally crosslinked nanostructures for combined optical imaging and therapy MALLINCKRODT LLC 2013-03-27 CN disclosed
US-7273904-B2 Nanocrystals in ligand boxes exhibiting enhanced chemical, photochemical, and thermal stability, and methods of making the same THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2007-09-25 US disclosed
US-20050004293-A1 Nanocrystals in ligand boxes exhibiting enhanced chemical, photochemical, and thermal stability, and methods of making the same NAJING TECHNOLOGY CORPORATION LIMITED (CN) 2005-01-06 US disclosed
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US disclosed
EP-1463505-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Abbott Laboratories (US) 2004-10-06 EP disclosed
WO-2004031732-A2 NANOCRYSTALS IN LIGAND BOXES EXHIBITING ENHANCED CHEMICAL, PHOTOCHEMICAL, AND THERMAL STABILITY, AND METHODS OF MAKING THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2004-04-15 WO disclosed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US disclosed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US disclosed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 WO disclosed
US-5648368-A ANTICOAGULANTS MERCK & CO., INC. (US) 1997-07-15 US disclosed
EP-0673247-A4 FIBRINOGEN RECEPTOR ANTAGONISTS. MERCK & CO INC (US) 1996-05-01 EP disclosed
EP-0673247-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1995-09-27 EP disclosed
WO-1994012181-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1994-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187026-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ALOX15 4082/4885LMNA 3109/4885HSD17B10 2153/4885
US-20030199511-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ALOX15 4082/4885LMNA 3109/4885HSD17B10 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.